Advertisement

NxStage Medical touts its 3rd European regulatory win this month with CE Mark approval for its OneSite single needle dialysis technology.

NxStage Medical logo

Massachusetts medical device maker NxStage Medical (NSDQ:NXTM) is on a roll, notching its 3rd regulatory win this month with CE Mark approval in the European Union for its OneSite single needle for dialysis patients.

The OneSite needle is part of NxStage's System One, which the company calls "the 1st and only truly portable hemodialysis system" with FDA clearance for home use.

Advertisement
Advertisement